Clinical Trials
35 trialsB7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
University of Pennsylvania
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Beijing Biotech
VEGAS
Baylor College of Medicine
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
SELECT-2CAR
Beijing Biotech
GRAIN
Baylor College of Medicine
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
DUAL-NK-NB
Beijing Biotech
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
DUAL-CAR-NK-GB
Beijing Biotech
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
University of California, San Francisco
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
City of Hope Medical Center
SELECT-CAR-NK
Essen Biotech
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
B7-H3.CD28Z.CART in CNS Neoplasms
Dana-Farber Cancer Institute
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Stanford University
B7-H3.CD28Z.CART in Solid Tumors
Dana-Farber Cancer Institute
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
BAH2472
Essen Biotech
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Cancer Research UK
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Haploidentical Stem Cell Transplantation in Neuroblastoma
Lund University Hospital
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
M.D. Anderson Cancer Center
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
Milton S. Hershey Medical Center
GINAKIT
Baylor College of Medicine
Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
Beijing Sanbo Brain Hospital
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
Beijing Sanbo Brain Hospital
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
Columbia University